| 查看: 3131 | 回复: 7 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
【求助】发（（很多金币））求一个新药的信息
|
|||
|
商品名： Mepact 通用名：米伐木肽(mifamurtide) 分子式： C59H109N6O19P CAS登记号：83461-56-7 2009年获欧盟批准上市 求：此化合物的 1.理化性质 2.制剂、处方、工艺及分析检测 3.药理、毒性、药代 有来源出处更好，能有多少就给多少信息， 已有的就可以了，结束，谢谢回复 [ Last edited by wo668668 on 2011-1-2 at 23:52 ] |
回复此楼» 猜你喜欢
26有没有老师想收做定量药理的学生啊
已经有3人回复
-
26考博申请 学or专
已经有15人回复
-
药物学论文润色/翻译怎么收费?
已经有281人回复
-
2026年山东大学海洋学院生物与医药博士招生-李霞课题组
已经有0人回复
-
博士研究生招生
已经有0人回复
-
药理学、临床药学方向 调剂
已经有1人回复
-
NSCLC脑转移肿瘤模型
已经有0人回复
-
CHP-134这个细胞系哪里有？
已经有0人回复
-
国自然意见求助
已经有74人回复
» 本主题相关商家推荐: (我也要在这里推广)
» 本主题相关价值贴推荐，对您同样有帮助:
- 【原创】多个1类临床前新药寻求合作和转让（DPP4,GLP-1,替尼类临床前新结构）
已经有26人回复
- 【求助】求助一个化合物的合成方法
已经有4人回复
- 【求助】20枚金币求助一个药品的销售额
已经有23人回复
- 【求助】新药立项信息查询如何操作
已经有10人回复
- 【求助】一个刚入手工艺员的疑惑
已经有17人回复
- 【求助】一个缓释片在体内达到哪些药动学参数才能算12h缓释？
已经有5人回复
- 【求助】关于一个药品发补延期的问题
已经有7人回复
» 抢金币啦！回帖就可以得到:
-
面上中了，散金币。
+5/1420
-
云南大学丁军桥团队2027年博士招生
+1/945
-
【半导体薄膜代工】ALD/CVD/磁控溅射/热蒸发全工艺
+1/95
-
南方科技大学刘科院士团队诚聘矿物浮选分离方向研究助理
+1/93
-
原子层沉积（ALD）磁控溅射PECVD等微纳代工服务：18817872921
+1/91
-
东南大学能源与环境学院-林日琛教授课题组-27级博士招生
+1/88
-
东南大学能源与环境学院-林日琛教授课题组-27级博士招生
+1/87
-
很认可这句话
+1/78
-
今日少年明日老。
+1/71
-
中南大学化学化工学院喻桂朋教授团队诚聘博士后（复合材料方向）
+1/37
-
深圳大学刘翼振课题组诚聘博士后（CRISPR分子诊断）
+1/36
-
四川大学高分子学院、空天学院招收研究助理
+1/17
-
中南大学化学化工学院喻桂朋教授团队诚聘博士后（复合材料方向）
+1/16
-
中南大学化学化工学院喻桂朋教授团队诚聘博士后（复合材料方向）
+1/14
-
中国科学院 理化技术研究所 招 动力工程及工程热物理 相近的保送硕士 博士
+1/11
-
湖南大学张旺课题组招收研究助理
+1/9
-
北京师范大学（珠海）化学传感与成像课题组2026年研究生（统招/推免）招生
+1/7
-
课题快结题了才发现没东西可申请专利？四个维度帮你挖一挖
+1/2
-
项目助理招聘启事
+1/2
-
香港大学智能制造实验室招收27年春秋季入学全奖博士和硕士研究生
+1/1
★
小木虫(金币+0.5):给个红包，谢谢回帖交流
wo668668(金币+5): 2011-01-02 23:53:03
小木虫(金币+0.5):给个红包，谢谢回帖交流
wo668668(金币+5): 2011-01-02 23:53:03
|
Information Generic Name: mifamurtide Trade Name: Mepact (EU), Junovan (US) Synonym: MTP-PE, muramyl tripeptide phosphatidylethanol Entry Type: New chemical entity Category BNF Category: Other antineoplastic drugs (08.01.05) Pharmacology: Liposomal formulation of muramyl tripeptide phosphatidylethanolamine Epidemiology: Osteosarcoma is a rare disease, with about 1,200 new cases in Europe each year (12). 2-3% of all childhood cancers are osteosarcoma with survival at 60-65% (11) Indication: Osteosarcoma Additional Details: non-metastatic, resectable Developmental Status UK: Launched EU: Launched US: Pre-registration (Filed) UK launch Plans: Available only to registered users Actual UK launch date: 01/02/2010 Method(s) of Administration Intravenous Comments Feb 10: Launched in EU [13]. 06/02/2010 16:58:41 Jun 09: Takeda have taken over the originator company (May 09). EU launch delayed until 2010 (personal communication). 19/06/2009 12:15:04 Mar 09: Company plan to submit an amended NDA to FDA mid-2009 after receiving a non-approvable letter, requesting more data, in Aug 08 (10) 09/03/2009 19:35:10 Mar 09: Licensed in EU (10) 09/03/2009 19:21:55 EU CHMP positive opinion for the treatment of patients with non-metastatic, resectable osteosarcoma, Nov 08. Recommendation to be adopted in Dec 08, with final approval 60-90days later. (9) 21/11/2008 09:35:23 CHMP opinion expected Q3 08, final decision anticipated Q4 08 (8) 09/04/2008 12:45:47 Confirmed plans to file in EU and expect to receive approval in 2007(1). Orphan drug status in EU and US (1). Plans to file in US in 06 (2). Filed in US Oct 06 (3). The FDA and the EMEA have designated Orphan Drug status to Junovan (3). Filed in EU Nov 06 (4). Negative opinion from FDA advisory committee May 07 (5). Non-approvable letter from FDA - more data required Aug 08 (6). 28/02/2008 09:51:04 Confirmed plans to file in EU and expect to receive approval in 2007(1). Orphan drug status in EU and US (1). Plans to file in US in 06 (2). Filed in US Oct 06 (3). The FDA and the EMEA have designated Orphan Drug status to Junovan (3). Filed in EU Nov 06 (4). Negative opinion from FDA advisory committee May 07 (5). Non-approvable letter from FDA - more data required Aug 08 (6). Company Information Name: Takeda US Name: IDM Pharma NICE Information In timetable: Yes When: Nov / 2010 Note: 17th wave, STA Prescribing Outlook: Available only to registered users Trial or other data Jul 10: in its draft guidance on mifamurtide, NICE has recommended against its use in combination with postoperative multi-agent chemotherapy in children, adolescents & young adults for treating high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection (14). 13/07/2010 09:49:30 Mar09: EU approval based on the Phase 3 MEPACT trial (INT-0133), a National Cancer Institute funded cooperative group study conducted by the Children′s Oncology Group and the largest study ever completed in osteosarcoma, enrolling approximately 800 patients. The study evaluated patient outcomes with the addition of mifamurtide to three- or four-drug adjuvant chemotherapy (cisplatin, doxorubicin, and methotrexate with or without ifosfamide). Results demonstrated that mifamurtide resulted in approximately a 30% decrease in the risk of death with 78% of patients surviving after six years of follow-up.(10) 09/03/2009 19:25:29 Filed in US for use in the treatment of newly diagnosed resectable high grade osteosarcoma following surgical resection in combination with multiple agent chemotherapy. IDM requested that the FDA consider granting priority review status, which could shorten review time from the standard ten months to six months if granted. The FDA customarily accepts or refuses to file NDAs and designates review status within 60 days of filing(3). Evidence Based Evaluations SMC http://www.scottishmedicines.org/smc/7718.html |
7楼2011-01-01 22:49:10
★
warlen(金币+1):谢谢参与 2010-12-31 09:40:37
wo668668(金币+10): 2010-12-31 12:52:08
warlen(金币+1):谢谢参与 2010-12-31 09:40:37
wo668668(金币+10): 2010-12-31 12:52:08
|
Systematic (IUPAC) name 2-[(N-{(2R)-[(2-acetamido-2,3-dideoxy-D-glucopyranos-3-yl)oxy]-propanoyl}-L-alanyl-D-isoglutaminyl-L-alanyl)amino]ethyl (2R)-2,3-bis(hexadecanoyloxy)propyl hydrogen phosphate Identifiers CAS number （1）83461-56-7 （2）838853-48-8 (mifamurtide sodium · xH2O) Chemical data Formula C59H109N6O19P Mol. mass 1237.499 g/mol SMILES eMolecules & PubChem Pharmacokinetic data Bioavailability N/A Half-life minutes (in plasma) 18 hrs (terminal) Therapeutic considerations Licence data EMA:Link Pregnancy cat. not investigated Legal status ℞ Prescription only Routes intravenous liposomal infusion over one hour muramylNAc-Ala-isoGln-Lys-tripeptide-PE Pharmacological Action Adjuvants, Immunologic [Link to MeSH] - Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The ... [show more] Adjuvants, Immunologic [Link to MeSH] - Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. [show less] Immunologic Factors [Link to MeSH] - Biologically active substances whose activities affect or play a role in the functioning of the immune system. Pharmacological Classification Chemical Actions and Uses [Link to MeSH] Pharmacologic Actions [Link to MeSH] Physiological Effects of Drugs [Link to MeSH] Immunologic Factors [Link to MeSH] Adjuvants, Immunologic [Link to MeSH] |
2楼2010-12-31 03:22:36
★
warlen(金币+1):谢谢参与 2010-12-31 09:40:42
wo668668(金币+10): 2010-12-31 12:49:24
warlen(金币+1):谢谢参与 2010-12-31 09:40:42
wo668668(金币+10): 2010-12-31 12:49:24
|
可以参考一下wiki百科 http://en.wikipedia.org/wiki/Mifamurtide |
3楼2010-12-31 08:54:24
★
warlen(金币+1):谢谢参与 2010-12-31 09:40:49
wo668668(金币+5): 2010-12-31 12:48:10
warlen(金币+1):谢谢参与 2010-12-31 09:40:49
wo668668(金币+5): 2010-12-31 12:48:10
|
欧洲批准米伐木肽(mifamurtide)注射剂上市 欧洲批准IDM Pharma公司的米伐木肽注射剂（mifamurtide，L-MTP-PE，:Mepact）上市，用于治疗非转移性可切除的骨肉瘤（少见但主要造成儿童和青年死亡的骨瘤）。本品是20余年来首个获准上市治疗骨肉瘤的新药。本品可在欧盟27个成员国以及冰岛、列支敦士登和挪威销售。 米伐木肽是20余年来首个改善骨肉瘤患者长期存活的药品。患者术前化疗，随后手术切除骨瘤，而后再化疗。当患者接受术后化疗的同时也静脉注射注射本品免疫治疗（一周2次，3个月，随后一周1次，6个月）。化疗如同炸弹摧毁肿瘤，而米伐木肽如同魔铲可彻底清除疾病显微战壕内的残留物。 米伐木肽通过刺激诸如巨噬细胞等某些白细胞来杀灭肿瘤细胞。本品制成球形脂质体，囊泡内是胞壁酰三肽（MTP）。此脂质触发巨噬细胞去消耗米伐木肽。一旦消耗完，MTP刺激尤其是在肝、脾和肺内的巨噬细胞去寻找肿瘤并杀灭之。 米伐木肽注射剂获准上市基于Ⅲ期临床研究结果。国立癌症研究所（NCI）建立的协作组，由儿童肿瘤组（COG）进行研究，完成本品治疗骨肉瘤最大研究课题在册的患者约800例。研究评价了米伐木肽与3～4种辅助化疗药（顺铂、多柔比星、甲氨蝶呤、有或无异环磷酰胺）联合用药的结果。研究显示，米伐木肽与化学药物联合使用可使死亡率降低约30%，78&经治疗的患者存活长达6年以上。 |
4楼2010-12-31 08:57:54
投票:
